Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Status:
Completed
Trial end date:
2021-05-27
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in
combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial
Ovarian Cancer (EOC).